American Heart Journal
Volume 151, Issue 3 , Pages 754.e7-754.e17 , March 2006

A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)–Prevenzione scoring

  • Alejandro Macchia, MD

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Giacomo Levantesi, MD

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Giovanna Borrelli, MSc

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Maria Grazia Franzosi, MSc

      Affiliations

    • Department of Cardiovascular Disease, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    • ,
  • Aldo Pietro Maggioni, MD

      Affiliations

    • Centro Studi ANMCO, Firenze, Italy
    • ,
  • RosaMaria Marfisi, MS

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Marco Scarano, MSc

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Luigi Tavazzi, MD

      Affiliations

    • IRCCS Policlinico San Matteo, Pavia, Italy
    • ,
  • Gianni Tognoni, MD

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Franco Valagussa, MD

      Affiliations

    • Ospedale San Gerardo, Monza, Italy
    • ,
  • Roberto Marchioli, MD

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • Corresponding Author InformationReprint requests: Roberto Marchioli, MD, Department of Clinical Pharmacology and Epidemiology, Laboratory of Clinical Epidemiology of Cardiovascular Disease, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy.
  • on behalf of Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)–Prevenzione Investigators

      Affiliations

    • The names of GISSI-Prevenzione Investigators are reported in reference.21

Received 6 April 2005 ,Accepted 13 October 2005.

References 

  1. Haffner SM, D'Agostino R, Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999;22:562–568
  2. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes. 1989;38:504–509
  3. Pan WH, Cedres LB, Liu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 1986;123:504–516
  4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  5. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360–367
  6. Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med. 2003;4(Suppl 6):S3–S10
  7. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909–915
  8. Charles MA, Fontbonne A, Thibult N, et al. Risk factors for NIDDM in white population. Paris prospective study. Diabetes. 1991;40:796–799
  9. Sicree RA, Zimmet PZ, King HOM, et al. Plasma insulin response among Nauruans: prediction of deterioration in glucose tolerance over 6 years. Diabetes. 1987;36:179–186
  10. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993;329:1988–1992
  11. Hunter SJ, Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med. 1998;105:331–345
  12. Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med. 2001;226:13–26
  13. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev. 1998;20:157–172
  14. Stern MP, Williams K, Haffner SM. Do we need the oral glucose tolerance test to identify future cases of type 2 diabetes?. Diabetes Care. 2003;26:940–941
  15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553
  17. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–252
  18. Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–1077
  19. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26:3153–3159
  20. Mitka M. Metabolic syndrome recasts old cardiac, diabetes risk factors as a “new” entity. JAMA. 2004;291:2062–2063
  21. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447–455
  22. Hosmer DW, Lemeshow S. Applied logistic regression. New York (NY): John Wiley & Sons, Inc; 1989;
  23. Bruzzi P, Green SB, Byar DP, et al. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol. 1985;122:904–914
  24. Walter SD. The distribution of Levin's measure of attributable risk. Biometrika. 1975;62:371–374
  25. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–1413
  26. Lowry R. Clinical Calculator 1 from an observed sample: estimates of population prevalence, sensitivity, specificity, predictive values, and likelihood ratios. Available from http://faculty.vassar.edu/lowry/clin1.html.2001;
  27. Silman AJ. Epidemiological studies: a practical guide. Cambridge (UK): Cambridge University Press; 1995;
  28. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristics curves: a nonparametric approach. Biometrics. 1988;44:837–845
  29. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515–524
  30. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36
  31. Neter J, Wasserman W. Multiple regression. In: Applied linear statistical models. Homewood (Ill): Irwin; 1974;p. 214–272
  32. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  33. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issue in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387
  34. Efron B, Tibshirani R. An introduction to the Bootstrap. New York (NY): Chapman and Hall; 1993;
  35. SAS Institute Inc., Cary, NC, U.S.A. SAS Institute Inc. . SAS/STAT Users Guide, Version 8. Cary (NC): SAS Institute Inc; 1999;
  36. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  37. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–3167
  38. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  39. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?. Ann Intern Med. 2002;136:575–581
  40. Levantesi G, Macchia A, Marfisi RM, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol. 2005;46:277–283
  41. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  42. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790–797
  43. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350
  44. Watkins LL, Sherwood A, Feinglos M, et al. Effects of exercise and weight loss on cardiac risk factors associated with syndrome X. Arch Intern Med. 2003;163:1889–1895

PII: S0002-8703(05)01007-0

doi: 10.1016/j.ahj.2005.10.023

American Heart Journal
Volume 151, Issue 3 , Pages 754.e7-754.e17 , March 2006

Article Tools

* Image Usage & Resolution